John B. Buse

5 ta ish

University of North Carolina at Chapel Hill

1. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

   Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen +12

   MaqolaOAOchiq kirish20164 iqtibos

   ABIABI:AkademIndex/2026.other.057706

2. Core–Shell Microneedle Gel for Self-Regulated Insulin Delivery

   Jinqiang Wang, Yanqi Ye, Jicheng Yu +9

   MaqolaOAOchiq kirish20182 iqtibos

   ABIABI:AkademIndex/2026.other.047399

3. Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs

   Jicheng Yu, Jinqiang Wang, Yuqi Zhang +7

   MaqolaOAOchiq kirish20202 iqtibos

   ABIABI:AkademIndex/2026.other.108085

4. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events

   John J McMurray, John J.V. McMurray, Steven M Haffner +51

   Maqola20102 iqtibos

   ABIABI:AkademIndex/2026.other.295648

5. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

   Melanie J. Davies, David A. D’Alessio, Judith Fradkin +7

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.472223